Allogene Therapeutics (ALLO) Insider Trading & Ownership $2.09 +0.14 (+7.18%) (As of 12/24/2024 05:19 PM ET) Add Compare Share Share Insider Trades Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends Allogene Therapeutics (NASDAQ:ALLO) Insider Buying and Selling ActivityCurrentInsider OwnershipPercentage24.30%Number OfInsiders Buying(Last 12 Months)2Amount OfInsider Buying(Last 12 Months)$5.00 MNumber OfInsiders Selling(Last 12 Months)2Amount OfInsider Selling(Last 12 Months)$66,041.84 Get ALLO Insider Trade Alerts Want to know when executives and insiders are buying or selling Allogene Therapeutics stock? Sign up for InsiderTrades.com's daily newsletter to get the latest insider transactions delivered to your inbox daily. Email Address ALLO Insider Buying and Selling by Quarter Ad DTIWill the Nasdaq 100 crash?In a world where some top money managers say you should “diversify” with a basket of stocks to help lower risk in your portfolio… And others say you should focus on only one ticker at a time because you can’t really keep detailed tabs on 10, 20 or more stocks at once… My #1 strategy to play the Nasdaq bull run has shown the power to provide the best of BOTH worlds at the same time. Because it harnesses ONE ticker that bottles up all the firepower of Apple, Nvidia, Tesla and more into one place… While I cannot promise future returns or against losses… This strategy targets major payouts OVERNIGHT!Click here to get the details. Allogene Therapeutics Insider and Congressional Trades History Insiders and Members of Congress Insiders Only Members of Congress Only Transaction Type Custom Range 1 Month 3 Months 6 Months Year-to-Date 1 Year 2 Years 3 Years Time Frame * Start Date * End Date Export to Excel Transaction DateNameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails12/9/2024Deborah M MessemerDirectorSell9,136$2.18$19,916.48 12/5/2024Franz B HumerDirectorSell9,221$2.16$19,917.36 5/30/2024Franz B HumerDirectorSell11,200$2.34$26,208.00 5/16/2024Arie BelldegrunDirectorBuy1,724,137$2.90$4,999,997.30 1/30/2024Geoffrey M ParkerCFOBuy190$3.60$684.00 (Data available from 1/1/2013 forward) ALLO Insider Trading Activity - Frequently Asked Questions Who is on Allogene Therapeutics's Insider Roster? The list of insiders at Allogene Therapeutics includes Alison Moore, Arie Belldegrun, David D Chang, Deborah M Messemer, Eric Thomas Schmidt, Franz B Humer, Geoffrey M Parker, Owen N Witte, Rafael Amado, Stephen Mayo, and Veer Bhavnagri. Learn more on insiders at ALLO. What percentage of Allogene Therapeutics stock is owned by insiders? 24.30% of Allogene Therapeutics stock is owned by insiders. Learn more on ALLO's insider holdings. Which Allogene Therapeutics insiders have been buying company stock? The following insiders have purchased ALLO shares in the last 24 months: Arie Belldegrun ($4,999,997.30), and Geoffrey M Parker ($684.00). How much insider buying is happening at Allogene Therapeutics? Insiders have purchased a total of 1,724,327 ALLO shares in the last 24 months for a total of $5,000,681.30 bought. Which Allogene Therapeutics insiders have been selling company stock? The following insiders have sold ALLO shares in the last 24 months: Deborah M Messemer ($70,244.48), Franz B Humer ($46,125.36), Stephen Mayo ($42,900.00), and Veer Bhavnagri ($41,670.00). How much insider selling is happening at Allogene Therapeutics? Insiders have sold a total of 64,197 Allogene Therapeutics shares in the last 24 months for a total of $200,939.84 sold. Allogene Therapeutics Key ExecutivesDr. Arie S. Belldegrun F.A.C.S. (Age 75)M.D., Co-Founder & Executive Chairman Compensation: $649.1kDr. David D. Chang M.D. (Age 64)Ph.D., Co-Founder, President, CEO & Director Compensation: $994.6kMr. Joshua A. Kazam (Age 47)Co-Founder & Director Compensation: $260.5kMr. Timothy L. Moore Ph.D. (Age 63)Executive VP & Chief Technical Officer Compensation: $554.35kDr. Zachary J. Roberts M.D. (Age 46)Ph.D., Executive VP of Research & Development and Chief Medical Officer Compensation: $747.39kMr. Geoffrey M. Parker (Age 59)Executive VP & CFO Ms. Annie Yoshiyama (Age 40)Senior VP, Corporate Controller & Principal Accounting Officer Mr. Earl M. Douglas Esq. (Age 61)Senior VP, General Counsel, Compliance Officer & Corporate Secretary Ms. Susan R. Lundeen (Age 58)Chief People Officer Ms. Christine CassianoExecutive VP, Chief Corporate Affairs & Brand Strategy Officer More Insider Trading Tools from MarketBeat Related Companies BioCryst Pharmaceuticals Insider Ownership Immunocore Insider Ownership Novavax Insider Ownership Vir Biotechnology Insider Ownership Anavex Life Sciences Insider Ownership Adaptive Biotechnologies Insider Ownership Poseida Therapeutics Insider Ownership LENZ Therapeutics Insider Ownership Replimune Group Insider Ownership Relay Therapeutics Insider Ownership Insider Tracking Tools CEO Purchases/Sales CFO Purchases/Sales Top Insider Buying Stocks Top Insider Selling Stocks Insider Trades Screener Insider Trades Newsletter Congressional Stock Trades Insider Trading By Country U.S. Insider Trading Activity Canadian Insider Trading Activity U.K. Insider Trading Activity Australia Insider Trading Activity Latest Articles AppLovin Insiders Sell Shares: Stock Price Indicated Higher Are 2024’s Top Insider Buys a Good Bet for 2025? Bargains Galore? 3 Stocks With Insider Buying in the MillionsInsiders Keep Buying These Stocks: 2 to Buy, 1 to AvoidZeta Global Holdings Insiders Buy Stock After Short-Report This page (NASDAQ:ALLO) was last updated on 12/26/2024 by MarketBeat.com Staff From Our Partners Is Starlink Set For The Largest IPO In History?He turned PayPal from a tiny, off-the-radar startup… to a massive $64 billion giant. Then, he did it again ...Paradigm Press | SponsoredDid You See Trump’s Bombshell Exec. Order 001?Starting with what I call Exec. Order 001. It’s a bombshell law that I believe Trump will sign within minut...Banyan Hill Publishing | SponsoredVladimir Lenin was right…The Magnificent 7 could be in for a world of pain… And the insiders know it. It’s why Jeff Bezos just sold ...Porter & Company | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowCrypto has officially entered the "banana zone" – that wild phase where prices can 1000x in days. It happen...Crypto Swap Profits | SponsoredNvidia’s Bold Move: Tackling Tech’s $1 Trillion CrisisTaiwan Semiconductor, a partner of Nvidia’s for more than two decades, has seen its shares explode as much as ...Weiss Ratings | SponsoredElon Musk could help pay for your retirementElon Musk is the richest man in the world... And he's pouring trillions into a unique investment.Brownstone Research | SponsoredTSLA *BANG* incoming (bullet in the chamber rn)I just pinpointed 5 dirt-cheap stocks that could soar the second the shot goes off. Thanks to Donald Trump’...StocksToTrade | SponsoredThe Key to Feeding 8.1 Billion PeopleImagine a mineral so small it fits in the palm of your hand... yet its potential could transform the world's f...i2i Marketing Group, LLC | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Allogene Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Allogene Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
